Related Experiment Video
Updated: Sep 24, 2025
06:46
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
439
Clarifications regarding bumetanide for neonatal seizures.
1Neurology Department, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Epilepsia
|May 7, 2022
Summary
Bumetanide shows promise as a neonatal seizure treatment, demonstrating efficacy without toxicity in a Phase II trial. Further multi-institutional studies are necessary to confirm its effectiveness as an adjunctive anticonvulsant.
Area of Science:
- Neonatal neurology
- Pharmacology
Background:
- Neonatal seizures are a critical concern in newborn care.
- Existing treatments for neonatal seizures have limitations.
- Bumetanide, a diuretic, has emerged as a potential adjunctive therapy.
Purpose of the Study:
- To evaluate the efficacy and safety of bumetanide as an adjunctive treatment for neonatal seizures.
- To address concerns regarding bumetanide's use as an anticonvulsant.
- To determine the need for further clinical trials.
Main Methods:
- Phase II randomized, controlled trial.
- Adjunctive administration of bumetanide.
- Assessment of efficacy signals and toxicity.
Main Results:
- A robust signal of efficacy was observed with bumetanide treatment.
- No evidence of toxicity was detected in the trial.
- The study suggests potential for bumetanide in neonatal seizure management.
Conclusions:
- Bumetanide demonstrates promising efficacy as an adjunctive treatment for neonatal seizures.
- The safety profile appears favorable, with no observed toxicity.
- A larger, multi-institutional trial is warranted to definitively establish efficacy.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
300
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
300
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
473
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
473
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
710
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
710
01:21Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
01:08Antiepileptic Drugs: Sodium Channel Blockers
1000
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
1000
01:18Drug Delivery: Enteral Route
792
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
792